Brief: Spruce Biosciences Provides Clinical Program Updates And Outlook For 2022
24/01/2022 13:12
Jan 24 (Reuters) - Spruce Biosciences Inc SPRB.O :
* SPRUCE BIOSCIENCES PROVIDES CLINICAL PROGRAM UPDATES AND
OUTLOOK
FOR 2022
* SPRUCE BIOSCIENCES INC - TOPLINE DATA FROM CAHMELIA-203
AND
CAHMELIA-204 ANTICIPATED IN 2H 2023 AND 2H 2024, RESPECTIVELY
* SPRUCE BIOSCIENCES INC - STRATEGIC REPRIORITIZATION
EXTENDS
ANTICIPATED CASH RUNWAY BY 6 MONTHS INTO Q2 2024
Source text for Eikon: ID:nBw5bB2qBa
Further company coverage: SPRB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spruce Biosciences
See all newsSpruce Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Spruce Biosciences Q2 net loss widens on higher expenses
Spruce Biosciences, Inc. expected to post a loss of $5.80 a share - Earnings Preview
Brief: Spruce Biosciences Appoints Adrian Quartel, M.D., Ffpm, As Chief Medical Officer
Brief: Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium